Literature DB >> 15721223

Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain.

Gad M Gilad1, Herbert M Kagan, Varda H Gilad.   

Abstract

The study is based on the premise that the enzyme lysyl oxidase (LO), which catalyzes the crosslinking of extracellular matrix (ECM) proteins, participates in ECM modulation and senile plaque formation in Alzheimer's disease (AD). Experiments on hippocampal samples indicate that LO activity is increased (about 30%) in AD, but also in non-Alzheimer's dementia, as compared to controls with unrelated diseases. Immunohistochemistry with specific LO antibody indicates localization in blood vessel walls and in plaque-like structures. The number of LO-positive plaque-like structures in AD was over two-fold higher as compared to both non-Alzheimer's dementia and control groups. The findings lead us to suggest that active LO molecules in the ECM may be associated with plaque formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15721223     DOI: 10.1016/j.neulet.2004.11.054

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Nna1 mediates Purkinje cell dendritic development via lysyl oxidase propeptide and NF-κB signaling.

Authors:  Jianxue Li; Xuesong Gu; Yinghua Ma; Monica L Calicchio; Dong Kong; Yang D Teng; Lili Yu; Andrew M Crain; Timothy K Vartanian; Renata Pasqualini; Wadih Arap; Towia A Libermann; Evan Y Snyder; Richard L Sidman
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

Review 2.  Human copper-dependent amine oxidases.

Authors:  Joel Finney; Hee-Jung Moon; Trey Ronnebaum; Mason Lantz; Minae Mure
Journal:  Arch Biochem Biophys       Date:  2014-01-06       Impact factor: 4.013

3.  Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase.

Authors:  Alexia Eliades; Nikolaos Papadantonakis; Ajoy Bhupatiraju; Kelley A Burridge; Hillary A Johnston-Cox; Anna Rita Migliaccio; John D Crispino; Hector A Lucero; Philip C Trackman; Katya Ravid
Journal:  J Biol Chem       Date:  2011-06-10       Impact factor: 5.157

4.  Effects of lysyl oxidase genetic variants on the susceptibility to rhegmatogenous retinal detachment and proliferative vitreoretinopathy.

Authors:  Honghua Yu; Tao Li; Xiulan Zou; Ling Yuan; Jie Hu; Zhe Xu; Lianghong Peng; Chu Zhang; Yuping Zou
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 5.  Oxidases and reactive oxygen species during hematopoiesis: a focus on megakaryocytes.

Authors:  Alexia Eliades; Shinobu Matsuura; Katya Ravid
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

6.  High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function.

Authors:  Argyrios Chronopoulos; Amanda Tang; Ekaterina Beglova; Philip C Trackman; Sayon Roy
Journal:  Diabetes       Date:  2010-09-07       Impact factor: 9.461

7.  Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer's disease.

Authors:  Catia Bellucci; Cinzia Lilli; Tiziano Baroni; Lucilla Parnetti; Sandro Sorbi; Carla Emiliani; Eleonora Lumare; Paolo Calabresi; Stefania Balloni; Maria Bodo
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

Review 8.  The rationale for targeting the LOX family in cancer.

Authors:  Holly E Barker; Thomas R Cox; Janine T Erler
Journal:  Nat Rev Cancer       Date:  2012-07-19       Impact factor: 60.716

9.  Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery.

Authors:  Qing Zhang; Xiao-Shun Jin; Zhong-Yin Yang; Min Wei; Xiao-Cheng Zhu; Ping Wang; Bing-Ya Liu; Qin-Long Gu
Journal:  Oncol Lett       Date:  2012-12-27       Impact factor: 2.967

Review 10.  The potential for targeting extracellular LOX proteins in human malignancy.

Authors:  Alejandro Mayorca-Guiliani; Janine T Erler
Journal:  Onco Targets Ther       Date:  2013-11-25       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.